Metrion collaborates with LifeArc on neuroscience-focused ion channel drug discovery project

Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK medical research charity, today announced they have entered into a collaboration agreement for an ion channel drug discovery project in the field of neuroscience.

The project aims to identify novel selective small molecule modulators of a specific ion channel target, which human patient gene association studies have identified as likely to be involved in neurological pathogenesis.

LifeArc will have responsibility for all new chemical syntheses with Metrion conducting ion channel screening.

Metrion will provide support for LifeArc’s medicinal chemistry target optimization via its extensive suite of drug discovery assays, including high quality automated and conventional electrophysiology, translational neuroscience, and cardiac safety profiling assays.

The project commenced in January 2019 and will run for an initial period of twelve months, with an option to extend for a further twelve months based upon achievement of mutually agreed criteria. If successful, LifeArc will be responsible for the further development of the program.

Metrion has a long standing working relationship with LifeArc, and we are very pleased to be working with the team again on this new project, on a highly promising neuroscience target.”

Dr Edward Stevens, Head of Drug Discovery, Metrion Biosciences

LifeArc is committed to advancing research in neuroscience, one of our three priority therapy areas. We are excited to be collaborating with Metrion as this provides powerful synergies which will deliver drug candidates that are suitable for onward development and which have real potential to help patients.

Dr Justin Bryans, Executive Director, Drug Discovery, LifeArc

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Metrion Biosciences Limited. (2019, June 19). Metrion collaborates with LifeArc on neuroscience-focused ion channel drug discovery project. News-Medical. Retrieved on October 14, 2024 from https://www.news-medical.net/news/20190130/Metrion-collaborates-with-LifeArc-on-neuroscience-focused-ion-channel-drug-discovery-project.aspx.

  • MLA

    Metrion Biosciences Limited. "Metrion collaborates with LifeArc on neuroscience-focused ion channel drug discovery project". News-Medical. 14 October 2024. <https://www.news-medical.net/news/20190130/Metrion-collaborates-with-LifeArc-on-neuroscience-focused-ion-channel-drug-discovery-project.aspx>.

  • Chicago

    Metrion Biosciences Limited. "Metrion collaborates with LifeArc on neuroscience-focused ion channel drug discovery project". News-Medical. https://www.news-medical.net/news/20190130/Metrion-collaborates-with-LifeArc-on-neuroscience-focused-ion-channel-drug-discovery-project.aspx. (accessed October 14, 2024).

  • Harvard

    Metrion Biosciences Limited. 2019. Metrion collaborates with LifeArc on neuroscience-focused ion channel drug discovery project. News-Medical, viewed 14 October 2024, https://www.news-medical.net/news/20190130/Metrion-collaborates-with-LifeArc-on-neuroscience-focused-ion-channel-drug-discovery-project.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Metrion Biosciences strengthens team with three key appointments